Our State-of-the-Art Review on Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses is now out on @JACCCardioOncology @JACCJournals 👇 https://t.co/4dovzIyTd0 Role of current multimodality imaging and future directions for their applications: 👥For

Evaluating changes in absolute coronary flow & microvascular resistance in patients with AS undergoing TAVI: no changes immediately after TAVI. Over time, remodelling of the left ventricle is assoc. with increased hyperaemic perfusion https://t.co/jrAOn35JEK @EuroInterventio

🎯 To assess the association of glucometabolic parameters w/ T4aMI in NSTEMI pts undergoing PCI. 🩸Admission blood glucose (ABG), glycated hemoglobin (HbA1c), and stress hyperglycemia ratio (SHR) were tested. 👥 Consecutive NSTEMI patients undergoing PCI from the AMIPE

We’re delighted to present our clinical case from the Cardiology Unit at Sant’Andrea University Hospital, showcasing the multidisciplinary management of a patient with HFrEF and multiple Valvular Heart Diseases. A special thank you to the @iheartfunction (iHF) Educational

Delighted to share our new study on the link between air pollution, chromatin remodeling and brown fat dysfunction 🧡 Kudos to #SanjayRajagopalan and team! https://t.co/4KStRMCyB9 Press release from @uzh: https://t.co/rOsBBKE1H5 @CardioZurich @Unispital_USZ #CTEC

🎯To quantify the cardiorenal benefits of combination regimens with GLP-1RA, SGLT2i, and/or finerenone versus corresponding monotherapies. 👥Systematic review and meta-analysis of post hoc analyses of RCTs and 10 observational studies that met prespecified inclusion criteria.

This could have been a “boring” STEMI activation. What happens when you wait for ST elevation to develop?

In patients with severe aortic stenosis, absolute coronary flow and microvascular resistance do not change immediately or 6 months after TAVI. Yet, reverse LV remodelling is associated with improved hyperaemic perfusion, highlighting the dynamic interaction between coronary flow,

Remember the recent HFrEF case shared by Mustafa Goktug Erata & Mehmet Birhan Yilmaz? Part 2 is now available: the case of a 36-year-old male patient diagnosed with Becker muscular dystrophy. ➡️ Find out which strategy the team selected: https://t.co/40J96MaOe8

Australian ACS guidelines 2025 - The OMI has officially arrived! - ED Guidelines. https://t.co/92GWWoe61W

10 Issues for the Clinician in Tricuspid Regurgitation: 2025 ACC EDCP  https://t.co/WVeKnC4OiW  @JACCJournals @ACCinTouch @escardio @purviparwani @iamritu

📌Sub-analysis of the EmDia trial (NCT02932436) 🎯To assess changes in lipid profiles driven by Empagliflozin use in HF patients. 👥 Lipid analysis of blood plasma from 144 pts was conducted using 4D-LC-TIMS/IMS lipidomics and repeated after one and twelve weeks of treatment.

Case by Mustafa Göktuğ Erata & Mehmet Birhan Yilmaz: 🧔🏻36-yo with Becker Muscular Dystrophy, ADHF 🔎 Echo: HFrEF, dilated LV ⚠️ Meets ESC advanced HF + several AHA “I NEED HELP” markers → ~46.5% 1-yr mortality How would you treat this patient? https://t.co/40J96MaOe8

📌DAPAHEART trial: a single-center, 4-week, randomized (1:1 dapagliflozin 10 mg vs. placebo), double-blind, controlled study. 🎯To assess the long-term impact of dapagliflozin on CFR and EAT thickness in T2DM patients with CAD. 👥N=16 pts w/ T2DM+CAD were enrolled in the

The 2025 ESC/EACTS guidelines on the management of valvular heart disease have just been released, with an important update: the age threshold for the Heart Team to consider TAVI instead of surgical intervention has been lowered from 75 to 70 years in patients with tricuspid

🔓 For a limited time until August 16, we are offering free promotional access to a new article in #CJC! 🌐 This study links CT-derived extracellular volume fraction (ECV) to diastolic function changes before and after TAVI. Findings highlight ECV's potential as a biomarker for

🎯New Review Highlights Adipose Tissue Drug Targets. Epicardial & perivascular adipose tissues (EAT & PVAT) are emerging as key players in cardiovascular disease -and now, as promising drug targets.🫀💊 This review dives into: ✅ DPP4, GLP-1R, SGLT-2i advances ✅ AT-specific

🔥 Published this month: Three NEW external validation studies all point to one conclusion: AI can detect acute coronary occlusion where contemporary ECG criteria fail!

💊 Can acetazolamide speed up decongestion in acute heart failure with volume overload? The ADVOR trial explored the effect of adding it to loop diuretics in ADHF hospitalised patients. A concise take by Hajer Yakoubi & Rim El Mejri↩️ https://t.co/Ma2SFUTsLo

🎯 Meta-analysis to provide the NNT and efficacy of GLP-1RA in reducing risk of myocardial infarction (MI). 👥109,846 pts from 25 studies. Risk-reduction effect of GLP-1RA were pooled using pairwise meta-analysis with a random-effects model. The primary outcome was MI, and

🫀 Cardiometabolic HFpEF phenotype (cmHFpEF) is rising fast, linked to obesity, hypertension, and chronic inflammation. 🔬 New insights reveal how metabolic stress, immune shifts, and epigenetic changes drive this condition. 🧬 Targeting metabolism, inflammation & chromatin